BANK VONTOBEL/CALL/REGENERON PHARMACEUTICALS/750/0.01/20.09.24 Share Price

Warrant

DE000VM2R281

Delayed Deutsche Boerse AG 08:12:16 21/05/2024 pm IST
2.43 EUR +4.29% Intraday chart for BANK VONTOBEL/CALL/REGENERON PHARMACEUTICALS/750/0.01/20.09.24
Current month+42.07%
1 month+36.26%
Date Price Change
21/24/21 2.43 +4.29%
20/24/20 2.33 +2.19%
17/24/17 2.28 +3.17%
16/24/16 2.21 -2.64%
15/24/15 2.27 -1.73%

Delayed Quote Deutsche Boerse AG

Last update May 21, 2024 at 08:12 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Vontobel Vontobel
WKN VM2R28
ISINDE000VM2R281
Date issued 21/09/2023
Strike 750 $
Maturity 20/09/2024 (122 Days)
Parity 100 : 1
Emission price 1.59
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.62
Lowest since issue 1.17
Spread 0.01
Spread %0.41%

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
987.3 USD
Average target price
1,042 USD
Spread / Average Target
+5.54%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW